有券商表示，创新药核心资产仍将上行，小核酸、体内CAR新机遇层出不穷。创新药BD是长期产业趋势，是中国创新药力量进入世界 舞台的价值兑现，对于已授权MNC的核心资产将随着临床进展持续兑现价值。除此以外，未来仍要锚定前沿技术平台，紧跟临床数据 进展。 （文章来源：每日经济新闻） 受盘面影响，多只创新药相关ETF跌近2%。 | 代码 | 类型 名称 | 现价 | 涨跌 涨跌幅 · | | --- | --- | --- | --- | | 589120 主 科创创新药ETF汇添富 | | 0.908 | -0.017 -1.84% | | 516080 主 创新药ETF易方达 | | 0.706 | -0.014 -1.94% | | 560900 | 主 创新药企ETF | 0.966 | -0.019 -1.93% | | 589720 主 科创创新药ETF国泰 | | 0.982 | -0.018 -1.80% | 创新药概念股走低，荣昌生物跌超10%，百利天恒、信立泰、迈威生物-U跌超3%。 ...

证券日报网讯 1月9日，迈威生物在互动平台回答投资者提问时表示，二级市场的股价受多重因素影 响，迈威生物对公司股票在二级市场的价格表现保持关注，并致力于发展主营业务，为股东提供更好的 投资回报。 （文章来源：证券日报） ...

证券日报网讯1月9日，迈威生物在互动平台回答投资者提问时表示，公司已经和知名AI领域企业深势 科技和英矽智能达成了战略合作。公司充分利用AI技术，主要在以下几个方面进行布局：1)采用多组学 分析及AI技术手段挖掘新的靶点及靶点组合；2)结合基因工程及AI大数据对抗体分子及ADC分子进行 优化和改造；3)利用AI技术在ADC领域助力新作用机制毒素的结构设计和成药性开发。公司积极推进生 物医药与AI技术深度融合，赋能创新药物研发，为患者带来疗效更好、可及性更强的生物创新药，满 足全球未被满足的临床需求。 ...

Core Viewpoint - The A-share market is experiencing a significant upward trend, with the Shanghai Composite Index returning to 4100 points for the first time in 10 years, driven by a strong performance in the innovative pharmaceutical sector, particularly the Sci-Tech Innovation Drug ETF Huatai (589120) which rose over 3% [1] Group 1: Market Performance - The Sci-Tech Innovation Drug ETF Huatai (589120) saw most of its constituent stocks surge, with notable increases such as Yuekang Pharmaceutical up over 10%, Zhixiang Jintai up over 8%, and Micron Biologics up over 6% [3] - The top ten constituent stocks of the ETF include major players in the pharmaceutical sector, with BeiGene (688235) rising by 1.77% and Aier Eye Hospital (688578) increasing by 2.18% [3] Group 2: Regulatory Support - A national drug supervision conference held from January 6 to 7 emphasized the need to actively support the pharmaceutical industry in enhancing quality and efficiency, alongside comprehensive reforms in drug regulation [4] Group 3: Innovation and Drug Approvals - Innovation remains a key theme in the Sci-Tech Innovation Drug sector, with recent announcements including Zhixiang Jintai's conditional listing application for a dual-antibody drug and Micron Biologics receiving approval for clinical trials of a new drug for pancreatic cancer [5] - BeiGene announced the conditional approval of its new BCL2 inhibitor, providing new treatment options for patients with chronic lymphocytic leukemia [6] - Rongchang Biologics is seeking breakthrough therapy designation for a new indication of its drug, which would mark a significant regulatory achievement for domestic ADC products [7] Group 4: Future Outlook - The Pacific Securities report anticipates that by 2026, the innovative drug sector will benefit from enhanced international capabilities and supportive industry policies, leading to increased market confidence and investment [8] - The report highlights that the average deal value for innovative drugs purchased from China by top multinational corporations is significantly higher than those from overseas, indicating a growing recognition of the value of Chinese innovative drugs in the global market [9]

Core Insights - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators" supported by solid data and market performance [1] - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking a historical high [1] - Shanghai's Pudong district is becoming a key hub for the global market, with significant achievements in CAR-T products and first-class new drugs [1] Industry Overview - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs in development worldwide [1] - The industry is entering a critical phase characterized by "innovation realization + global layout" [1] Company Developments - Chinese innovative drug companies are leveraging speed and cost-effectiveness to gain a competitive edge in the global market [3] - Companies like Maiwei Biotech and Jinsai Pharmaceutical are forming significant overseas business development (BD) partnerships, enhancing China's global competitiveness [3][4] - Maiwei Biotech has accelerated its BD efforts, securing exclusive licensing agreements for innovative therapies, including a $1 billion potential deal with Aditum Bio [4][5] Market Trends - By 2025, Pudong is expected to have approved four CAR-T products, accounting for 30% of the global total, and seven first-class new drugs, representing 14% of the national total [1] - The commercial sales of innovative drugs in Pudong are projected to exceed 11.6 billion yuan in 2024, with several new drugs achieving over 1 billion yuan in annual sales [10] Strategic Initiatives - Companies are focusing on building comprehensive global capabilities covering research, registration, and sales to transition from "licensing out" to "commercialization abroad" [10] - Jinsai Pharmaceutical has established local teams in the U.S. and Europe to manage clinical trials and seek collaboration opportunities [8] Innovation and Collaboration - The future of innovative drugs lies in international markets, with companies emphasizing deep understanding of disease biology as a core competitive advantage [5] - Companies are forming cooperative committees with BD partners to ensure project progress through information sharing and resource collaboration [5] Ecosystem Support - The rise of China's innovative drug industry is attributed to years of policy guidance, technological accumulation, and capital cultivation [23] - The unique industrial atmosphere, talent pool, and complete industrial chain in Zhangjiang are seen as core advantages for local companies [23][24] - Pudong's talent policies and supportive platforms are facilitating the rapid gathering of global talent resources [23] Future Outlook - The next 3-5 years are expected to see continued emphasis on internationalization and globalization among Chinese biopharmaceutical companies [14] - Companies are increasingly focusing on source innovation and high-quality BD potential to meet global market demands and achieve high valuations [17]

Core Viewpoint - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators," supported by solid data and market performance [1]. Group 1: Industry Overview - China's pharmaceutical industry is the second largest globally, with innovative drugs accounting for approximately 30% of global research [1]. - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking historical highs [1]. - The increase in competitiveness and cost-effectiveness of Chinese pharmaceutical assets is driving the industry into a critical phase of "innovation realization + global layout" [1]. Group 2: Regional Development - Shanghai's Pudong district is becoming a core hub for the global market connection of China's biopharmaceutical industry, with significant achievements in innovative drug approvals and business development transactions [1]. - By 2025, Pudong has approved 4 CAR-T products (30% of the global total) and 7 Class 1 new drugs (14% of the national total), with business development transaction amounts reaching $20.4 billion (14% of the global total) [1]. Group 3: Competitive Advantages - Chinese innovative pharmaceutical companies are gaining a competitive edge in the global market due to their speed and cost-effectiveness, being able to advance drug discovery 2-3 times faster and recruit clinical trial patients 2-5 times faster than international counterparts [3]. - The cost per patient for clinical trials in China is only half that of Europe and the US [3]. Group 4: Business Development Collaborations - Companies like Maiwei Biopharma and Jinsai Pharmaceutical are forming significant overseas business development collaborations, enhancing China's global competitiveness in innovative drugs [3][5]. - Maiwei Biopharma has accelerated its business development efforts, securing exclusive licensing agreements for innovative therapies within months of initial meetings [3][4]. Group 5: Full-Chain Layout - A number of innovative pharmaceutical companies are rapidly constructing comprehensive overseas layouts covering research, registration, and sales, transitioning from "licensing out" to "commercialization abroad" [9]. - By 2024, Pudong is expected to have over 20 innovative drugs achieving commercial sales, with total sales exceeding 11.6 billion yuan [9]. Group 6: Source Innovation - The market consensus is that only companies with source innovation capabilities, quality business development potential, and global layout abilities can effectively meet global market demands and achieve high valuations [16]. - Companies like Jinfang Pharmaceutical are focusing on unique therapeutic areas and avoiding following trends, which positions them favorably in the global market [17]. Group 7: Industry Ecosystem - The rise of China's innovative pharmaceutical industry is attributed to years of policy guidance, technological accumulation, and capital cultivation, leading to a critical growth inflection point [21]. - The unique industrial atmosphere, quality talent pool, and complete industrial chain in Zhangjiang are considered core advantages for companies operating in the region [21][22]. Group 8: Future Outlook - The Pudong district is set to enhance its support for the biopharmaceutical industry, aiming to become a global hub for innovative drug launches and scientific entrepreneurship [23]. - The ongoing development of a differentiated industrial linkage pattern is expected to further support the growth of the life sciences industry in the region [23]. Group 9: Conclusion - The path of globalization for Chinese innovative drugs is deepening, supported by core industrial hubs like Pudong and the continuous upgrading of companies' innovation and internationalization capabilities [24].

1月7日，A股市场创新药概念股集体上涨，其中，必贝特-U 20CM涨停，益诺思涨超17%，成都先导涨 超13%，盘龙药业10CM涨停，阳光诺和涨超9%，昭衍新药、前沿生物、迈威生物、益方生物涨超 7%，悦康药业涨超6%。 | 代码 | 名标 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688759 | 必贝特-U | 1 | 20.00 | 186亿 | 42.46 | | 688710 | 益裙思 | | 17.14 | 76.11亿 | 22.29 | | 688222 | 成都先导 | 1 | 13.48 | 122亿 | 29.59 | | 002864 | 盘龙药业 | | 10.00 | 37.06亿 | 13.07 | | 688621 | 阳光诺和 | | 9.28 | 81.88 Z | 17.63 | | 603127 | 昭衍新药 | 1 | 7.83 | 311亿 | 18.42 | | 688221 | 前沿生物-l * | | 7.72 | 2665.06 | 33.68 | | 68806 ...

格隆汇1月7日｜A股市场创新药概念股集体上涨，其中，必贝特-U 20CM涨停，益诺思涨超17%，成都 先导涨超13%，盘龙药业10CM涨停，阳光诺和涨超9%，昭衍新药、前沿生物、迈威生物、益方生物涨 超7%，悦康药业涨超6%。 | 代码 | 名标 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688759 | 1 必贝特-U | | 20.00 | 186亿 | 42.46 | | 688710 | 益裙思 | | 17.14 | 76.11亿 | 22.29 | | 688222 | 成都先导 | 1 | 13.48 | 122亿 | 29.59 | | 002864 | 盘龙药业 | | 10.00 | 37.06亿 | 13.07 | | 688621 | 阳光诺和 | | 9.28 | 81.88 Z | 17.63 | | 603127 | 昭衍新药 | 1 | 7.83 | 311亿 | 18.42 | | 688221 | 前沿生物-l * | | 7.72 | 2665.06 | 33.68 | | 68 ...

Core Insights - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "originators" in drug development, supported by solid data and market performance [1] - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking a historical high [1] - Shanghai's Pudong district is becoming a key hub for the global market, with significant achievements in CAR-T products and first-class new drugs [1] Industry Performance - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs in development worldwide [1] - Pudong has approved 4 CAR-T products, accounting for 30% of the global total, and 7 first-class new drugs, representing 14% of the national total [1] - Business development (BD) transaction amounts in Pudong reached $20.4 billion, making up 14% of the global total [1] Competitive Advantages - Chinese innovative drug companies are gaining a competitive edge in the global market due to their speed and cost-effectiveness, being able to advance drug discovery 2-3 times faster and recruit clinical trial patients at half the cost compared to Western counterparts [2] - Companies like Maiwei Biotech and Jinsai Pharmaceutical are establishing significant overseas BD collaborations, enhancing China's global competitiveness in innovative drugs [2] Strategic Collaborations - Maiwei Biotech has accelerated its BD efforts, forming exclusive licensing agreements for innovative therapies, including a collaboration with Calico Life Sciences for an IL-11 targeted therapy [2][3] - Jinsai Pharmaceutical's subsidiary has signed an exclusive licensing agreement with Yarrow Bioscience for a monoclonal antibody, with potential milestone payments totaling up to $1.365 billion [4] Full-Chain Development - A number of innovative drug companies are building comprehensive overseas strategies that cover research, registration, and sales, transitioning from "licensing out" to "commercialization abroad" [5] - By 2024, Pudong is expected to have over 20 innovative drugs achieving commercial sales, with total sales exceeding 11.6 billion yuan [5] Global Market Positioning - Junshi Bioscience's innovative drug has become a benchmark for commercialization abroad, having been approved in over 40 countries and regions [5][6] - The core challenge for Chinese companies in international markets is to ensure their products meet local medical needs, requiring innovation, efficacy, and safety [5] Talent and Ecosystem - The rise of China's innovative drug industry is supported by years of policy guidance, technological accumulation, and capital cultivation, with a strong emphasis on the importance of a mature industrial ecosystem [12] - Pudong's unique industrial atmosphere, talent pool, and complete industrial chain are critical advantages for local companies [12][13] Future Outlook - The Pudong district plans to enhance its support for the life sciences industry, aiming to become a global hub for innovative drugs and medical devices by 2025 [15] - The industry anticipates that internationalization will remain a core development trend for domestic biopharmaceutical companies over the next 3-5 years [7][8]

Core Viewpoint - Maiwei Biotech announced that its adalimumab injection 9MW0113 (domestic brand name: Junmaikang®) has received registration approval from the Indonesian Food and Drug Authority (BPOM), marking it as the first adalimumab biosimilar independently developed in China to gain such approval in Indonesia [1] Group 1 - 9MW0113 was co-developed by Maiwei Biotech and Junshi Bioscience [1] - The product has been formally partnered in over ten countries, indicating a strong international collaboration strategy [1] - Registration application documents have been submitted to multiple countries, including Jordan and Peru, showcasing the company's global expansion efforts [1]